/HUM
HUM Stock - Humana Inc.
Healthcare|Medical - Healthcare PlansNYSE
$259.40-0.49%
$1.27 (-0.49%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).71
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.5%upside
Target: $286.64
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HUM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$256.81 – $261.99
TARGET (TP)$286.60
STOP LOSS$238.65
RISK/REWARD1:1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$315.35
52W Low$206.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $117.76B | $106.37B | $92.87B | $83.06B | $77.16B |
| Gross Profit | $117.76B | $106.37B | $92.87B | $83.06B | $77.16B |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $1.72B | $3.38B | $3.57B | $3.35B | $4.60B |
| Net Income | $1.21B | $2.49B | $2.81B | $2.93B | $3.37B |
| Net Margin | 1.0% | 2.3% | 3.0% | 3.5% | 4.4% |
| EPS | $10.01 | $20.09 | $22.20 | $22.79 | $25.47 |
Company Overview
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
33%
Hold / Neutral
13
54%
Sell / Underperform
3
13%
Analyst Consensus🔴 Bearish
8 Bullish16 Neutral/Bearish
Price Targets
$377
Average Target
↑ 45.5% Upside
Now
$7
Low
$377
Average
$652
High
Based on 27 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2025 | Jefferies | Upgrade | Buy | $313 |
| October 14th 2025 | Goldman | Initiation | Sell | $235 |
| September 22nd 2025 | Evercore ISI | Initiation | In-line | $295 |
| May 1st 2025 | Raymond James | Upgrade | Outperform | $315 |
| November 6th 2024 | BofA Securities | Upgrade | Neutral | $308← $247 |
| October 11th 2024 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| October 8th 2024 | Bernstein | Upgrade | Outperform | $308 |
| October 7th 2024 | TD Cowen | Downgrade | Hold | $261← $402 |
| October 7th 2024 | Jefferies | Downgrade | Hold | $253← $519 |
| October 3rd 2024 | Piper Sandler | Downgrade | Neutral | $274← $392 |
| October 2nd 2024 | BofA Securities | Downgrade | Underperform | $247← $376 |
| October 2nd 2024 | Leerink Partners | Downgrade | Market Perform | $250← $400 |
| October 2nd 2024 | Stephens | Downgrade | Equal Weight | $250← $400 |
| June 26th 2024 | Piper Sandler | Initiation | Overweight | $392 |
| June 24th 2024 | Morgan Stanley | Initiation | Equal Weight | $374 |
Earnings History & Surprises
HUMBeat Rate
94%
Last 18 quarters
Avg Surprise
+5.9%
EPS vs Estimate
Beats / Misses
17/1
Last 12 quarters
Latest EPS
$3.24
Q4 2025
EPS Surprise History
Q1 24
-57.1%
$-0.11vs$-0.07
Q2 24
+18.1%
$7.23vs$6.12
Q3 24
+19.0%
$6.96vs$5.85
Q4 24
+22.4%
$4.16vs$3.40
Q1 25
+3.1%
$-2.16vs$-2.23
Q2 25
+15.0%
$11.58vs$10.07
Q3 25
+5.9%
$6.27vs$5.92
Q4 25
+10.6%
$3.24vs$2.93
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $-4.00 | — | — | — |
Q4 2025 | Nov 5, 2025 | $2.93 | $3.24 | +10.6% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $5.92 | $6.27 | +5.9% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $10.07 | $11.58 | +15.0% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $-2.23 | $-2.16 | +3.1% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $3.40 | $4.16 | +22.4% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $5.85 | $6.96 | +19.0% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $6.12 | $7.23 | +18.1% | ✓ BEAT |
Q1 2024 | Jan 25, 2024 | $-0.07 | $-0.11 | -57.1% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $7.16 | $7.78 | +8.7% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $8.82 | $8.94 | +1.4% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $9.27 | $9.38 | +1.2% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $1.46 | $1.62 | +11.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $6.28 | $6.88 | +9.6% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $7.67 | $8.67 | +13.0% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $6.78 | $8.04 | +18.6% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $1.23 | $1.24 | +0.8% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $4.61 | $4.83 | +4.8% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $6.86 | $6.89 | +0.4% | ✓ BEAT |
Latest News
President Trump Says We Could Get Insurance Companies To Cut Prices To Stay In System; I Will Call Meeting Of Insurance Companies To Get Their Price Down; Meeting In Coming Weeks
📈 PositiveBenzinga•Dec 19, 2025, 08:03 PM•Also: , ,
Morgan Stanley Maintains Equal-Weight on Humana, Lowers Price Target to $262
➖ NeutralBenzinga•Dec 18, 2025, 05:58 PM
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralBenzinga•Dec 18, 2025, 04:27 PM•Also: , ,
Humana Announces Insurance Leadership Transition; George Renaudin To Retire As Insurance Segment President By Q3 2026; Aaron Martin To Join As President Of Medicare Advantage And Insurance Segment President Successor; John Barger To Succeed Martin As President Of Medicare Advantage
➖ NeutralBenzinga•Dec 16, 2025, 01:12 PM
Shares of healthcare stocks are trading higher amid the Republican healthcare bill failing to win enough votes to advance in the Senate.
📈 PositiveBenzinga•Dec 11, 2025, 07:46 PM•Also: , ,
Humana shares are trading higher after Jefferies upgraded the stock to Buy and raised its price target from $253 to $313.
📈 PositiveBenzinga•Dec 5, 2025, 03:18 PM•Also:
Jefferies Upgrades Humana to Buy, Raises Price Target to $313
📈 PositiveBenzinga•Dec 5, 2025, 01:41 PM•Also:
CNBC Halftime Report Final Trades: Uber Technologies, Humana, Zoetis, Zoom Communications
➖ NeutralBenzinga•Nov 25, 2025, 06:01 PM•Also: , ,
'Humana to Appeal Ruling Upholding Medicare Star Bonus Cuts' - Bloomberg News
📉 NegativeBenzinga•Nov 25, 2025, 04:23 PM
Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $234
➖ NeutralBenzinga•Nov 25, 2025, 02:54 PM•Also:
Reuters: Some States Operating ACA Marketplaces Say Enrollment Is Significantly Down From Same Period Last Year, California Says ACA Enrollment Down By 33% vs Last Year
📉 NegativeBenzinga•Nov 24, 2025, 07:22 PM•Also: , ,
Shares of healthcare stocks are trading higher after Politico reported the White House will propose a two-year extension of Obamacare subsidies with new limits on eligibility.
📈 PositiveBenzinga•Nov 24, 2025, 01:00 PM•Also: , ,
Politico Reported The White House To Propose A Two-year Extension Of Obamacare Subsidies With New Limits On Eligibility
➖ NeutralBenzinga•Nov 24, 2025, 11:16 AM•Also: , ,
Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
📈 PositiveBenzinga•Nov 20, 2025, 12:34 PM•Also:
Shares of health insurers are trading higher amid a possible rebound after President Trump recently proposed that healthcare funding should go directly to people. On Monday, the Senate passed its shutdown-ending bill that lacked a provision to extend Obamacare subsidies; however, the Democrats secured a commitment to vote on credits in December.
📈 PositiveBenzinga•Nov 12, 2025, 05:44 PM•Also: , ,
Truist Securities Maintains Hold on Humana, Lowers Price Target to $285
📉 NegativeBenzinga•Nov 10, 2025, 04:44 PM
Shares of healthcare stocks are trading lower after the US Senate approved a deal clearing the path to ending the government shutdown. The deal does not include an extension of expiring Affordable Care Act subsidies
📉 NegativeBenzinga•Nov 10, 2025, 04:12 PM•Also: , ,
Watching Health Care Stocks; Traders Circulate Report Saying Speaker Johnson Says Won't Promise A Vote On Health-Care Subsidies
📉 NegativeBenzinga•Nov 6, 2025, 03:53 PM•Also: , ,
Humana shares are trading lower after the company cut its FY2025 GAAP EPS guidance.
📉 NegativeBenzinga•Nov 5, 2025, 12:25 PM
Humana Lowers FY2025 GAAP EPS Guidance from $13.77 to $12.26 vs $13.77 Est
📉 NegativeBenzinga•Nov 5, 2025, 11:01 AM
Frequently Asked Questions about HUM
What is HUM's current stock price?
Humana Inc. (HUM) is currently trading at $259.40 per share. The stock has moved -0.49% today.
What is the analyst price target for HUM?
The average analyst price target for HUM is $286.60, based on 1 analyst.
What sector is Humana Inc. in?
Humana Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Plans industry. The company is traded on the NYSE exchange.
What is HUM's market cap?
Humana Inc. has a market capitalization of $31.20 billion, making it a large-cap company.
Does HUM pay dividends?
No, Humana Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$137.24
Mkt Cap: $38.9B
ALC
Alcon Inc.
$79.97
Mkt Cap: $39.6B
CNC
Centene Corporation
$39.03
Mkt Cap: $19.2B
GEHC
GE HealthCare Technologies Inc.
$82.89
Mkt Cap: $37.9B
HLN
Haleon plc
$9.90
Mkt Cap: $44.9B
INSM
Insmed Incorporated
$174.84
Mkt Cap: $37.3B
IQV
IQVIA Holdings Inc.
$220.66
Mkt Cap: $37.6B
MTD
Mettler-Toledo International Inc.
$1402.51
Mkt Cap: $28.7B
ONC
BeOne Medicines Ltd.
$316.05
Mkt Cap: $33.8B
RMD
ResMed Inc.
$244.94
Mkt Cap: $35.9B
Explore stocks similar to HUM for comparison